New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
16:25 EDTLOW, INTC, TSN, LGND, GSK, DMND, LRNOn The Fly: Closing Wrap
Stocks on Wall Street were higher after the averages all advanced sharply at the open and maintained gains through the trading day. Optimism about hopes for a resolution to the fiscal cliff helped push stocks into positive territory Friday and that positive momentum carried over as the new week began. Positive economic data from the National Association of Realtors also buoyed investor confidence on the day... ECONOMIC EVENTS: In the U.S., the National Association of Realtors said that resales of existing homes climbed 2.1% last month to a seasonally adjusted annual rate of 4.79M units, beating forecasts for sales to have declined 0.2% from the prior month. The housing market index for November, a barometer of homebuilder sentiment, rose to 46, versus expectations for a flat 41 reading... COMPANY NEWS: Lowe's (LOW) reported earnings per share with charges that met expectations and revenue that beat consensus, sending shares higher $1.98, or 6.19%, to $33.96... Intel's (INTC) CEO Paul Otellini announced plans to retire in May and shares leveled off after some early day volatility, ending up 6c, or 0.30%, to $20.25... MAJOR MOVERS: Among the notable gainers was Tyson Foods (TSN), advancing $1.84, or 10.90%, to $18.72 after its quarterly earnings beat consensus and the company raised its regular dividend and declared a special dividend. Also higher were shares of Ligan Pharmaceuticals (LGND), up $2.40, or 14.40%, to $19.07 after the company's partner GlaxoSmithKline (GSK) said the FDA approved a new indication for its supportive care treatment for a condition associated with chronic hepatitis C. Among noteworthy losers was (DMND), down $1.79 or 11.83%, to $13.34 after the stock was downgraded to Underperform from Hold at Jeffries. Also lower were shares of K12 (LRN), down $3.84, or 18.78%, to $16.61 following a downgrade to Market Perform at Wells Fargo prompted by issues at one of its schools in Colorado. The company said in a midday release that it has been working "for some time" with Colorado Virtual Academy to address the performance issues that have arisen there... INDICES: The Dow was up 207.65, or 1.65%, to 12,795.96; the Nasdaq was up 62.94, or 2.21%, to 2,916.07; and the S&P 500 was up 27.01, or 1.99%, to 1,386.89.
News For LOW;INTC;TSN;LGND;GSK;DMND;LRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 22, 2014
08:18 EDTINTCVCE to become an EMC company
Subscribe for More Information
07:52 EDTINTCIntel recent weakness a buying opportunity, says Jefferies
Subscribe for More Information
07:49 EDTGSKGlaxoSmithKline sees FY14 dividend to rise 3% to 80p, 2015 dividend flat
Subscribe for More Information
07:48 EDTGSKGlaxoSmithKline announces restructuring program for pharmaceuticals business
Subscribe for More Information
07:46 EDTGSKGlaxoSmithKline to explore IPO of minority shareholding in ViiV Healthcare
Glaxo announced "further significant steps" within its Pharmaceuticals business to realize value for shareholders and deliver improved operational performance. Glaxo stated: "Five years ago, we created ViiV Healthcare, a new standalone global business focused on development of treatments for HIV. This has been a highly innovative and successful venture with our equity partners Pfizer and Shionogi. The business has made very significant progress in both R&D and commercial execution, culminating in the recent successful launches of Tivicay and Triumeq. We believe now is the right time to explore the potential for an IPO of a minority shareholding in this business. This will provide greater visibility of the intrinsic value we see in its currently marketed assets and future pipeline and also enhance potential future strategic flexibility."
07:44 EDTGSKGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
07:42 EDTGSKGlaxoSmithKline reports Q3 core EPS 27.9p, up 5% CER ex-divestments
Subscribe for More Information
06:44 EDTINTCIntel may face challenges over CPU product line in 2Q15, DigiTimes reports
Subscribe for More Information
06:41 EDTGSKWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
06:26 EDTINTCIntel Capital announces investments from China Smart Device Innovation Fund
Subscribe for More Information
October 21, 2014
11:04 EDTGSKGlaxoSmithKline receives orphan status for dabrafenib
The FDA granted GlaxoSmithKline orphan status for dabrafenib, its possible treatment of patients with BRAF mutation positive non-small cell lung cancer.
07:06 EDTGSKFierce Biotech to hold a breakfast meeting
Subscribe for More Information
06:15 EDTINTCIntel may stop providing subsidies for mobile solutions, DigiTimes reports
Intel may stop providing subsidies for mobile device solutions to eliminate loses from the business, reports DigiTimes. According to sources from PC players, however, Intel is likely to continue offering subsidies to some of its larger clients, like Asustek Computer, through different methods in order to maintain orders. Reference Link
October 20, 2014
09:09 EDTGSKEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:19 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
October 17, 2014
16:55 EDTINTCStocks end volatile week lower amid oil price plunge
Subscribe for More Information
14:50 EDTGSKBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
09:07 EDTTSNProtein stock pullback on Sanderson comments overdone, says BMO Capital
BMO Capital views yesterday's decline in Sanderson Farms (SAFM), Pilgrim's Pride (PPC) and Tyson Foods (TSN) as an overreaction to Sanderson's comments regarding breast prices falling to year-ago levels for the next four months. BMO notes that breast prices always dip in the fall. Following Sanderson's investor day, BMO said it sees a greater probability of chicken margins remaining at near-record levels in 2015. It keeps an Outperform rating on the stock.
07:39 EDTTSNChicken stock sell-off yesterday overdone, says JPMorgan
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use